New Phase 3 data show that adding perioperative immunotherapy can extend outcomes for resectable lung cancer. In final results from the Phase 3 IMpower030 study, patients with resectable stage II–IIIB non-small cell lung cancer treated with atezolizumab plus platinum chemotherapy before and after surgery achieved significantly longer event-free survival than those receiving chemotherapy alone. The findings strengthen the role of checkpoint inhibition in the perioperative setting for earlier-stage NSCLC, where treatment decisions must balance durable benefit with surgical feasibility and toxicity management. The trial’s design mirrors a broader push toward “treat beyond induction” strategies when systemic immune activation is maintained after resection. With these final data in hand, oncologists will likely reassess adjuvant and neoadjuvant pathways for operable patients and benchmark future trials against an atezolizumab-based perioperative standard.